Abstract
Harmine 1 was extracted from the seeds of Peganum harmala. From this natural molecule, a new series of isoxazole derivatives with complete regiospecificity were prepared using 1,3-dipolar cycloaddition reactions with various arylnitrile oxides. Harmine and its derivatives were characterized by 1H NMR, 13C NMR and HRMS. The evaluation of their anti-acetylcholinesterase (AChE), anti-5-lipoxygenase (5-LOX), anti-xanthine oxidase (XOD) and anticancer activities were studied in vitro against AChE, 5-LOX and XOD enzymes, respectively, and in HTC-116, MCF7 and OVCAR-3 cancer cell lines. The prepared derivatives were shown to be inactive against the XOD enzyme (0-38.3±1.9% at 100 M). Compound 2 exhibited the best anti-AChE activity (IC50=1.9±1.5 µM). Derivatives 3a, 3b and 3d had moderate cytotoxic activities (IC50=5.0±0.3 µM (3a) and IC50=6.3±0.4 µM (3b) against HCT 116 cells, IC50=5.0±1.0 µM (3d) against MCF7 cells).
Keywords: Peganum harmala, harmine, isoxazoles, anti-inflammatory, anti-xanthine oxidase, anticancer.
Medicinal Chemistry
Title:Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities
Volume: 12 Issue: 2
Author(s): Insaf Filali, Anis Romdhane, Mansour Znati, Hichem B. Jannet and Jalloul Bouajila
Affiliation:
Keywords: Peganum harmala, harmine, isoxazoles, anti-inflammatory, anti-xanthine oxidase, anticancer.
Abstract: Harmine 1 was extracted from the seeds of Peganum harmala. From this natural molecule, a new series of isoxazole derivatives with complete regiospecificity were prepared using 1,3-dipolar cycloaddition reactions with various arylnitrile oxides. Harmine and its derivatives were characterized by 1H NMR, 13C NMR and HRMS. The evaluation of their anti-acetylcholinesterase (AChE), anti-5-lipoxygenase (5-LOX), anti-xanthine oxidase (XOD) and anticancer activities were studied in vitro against AChE, 5-LOX and XOD enzymes, respectively, and in HTC-116, MCF7 and OVCAR-3 cancer cell lines. The prepared derivatives were shown to be inactive against the XOD enzyme (0-38.3±1.9% at 100 M). Compound 2 exhibited the best anti-AChE activity (IC50=1.9±1.5 µM). Derivatives 3a, 3b and 3d had moderate cytotoxic activities (IC50=5.0±0.3 µM (3a) and IC50=6.3±0.4 µM (3b) against HCT 116 cells, IC50=5.0±1.0 µM (3d) against MCF7 cells).
Export Options
About this article
Cite this article as:
Filali Insaf, Romdhane Anis, Znati Mansour, Jannet B. Hichem and Bouajila Jalloul, Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities, Medicinal Chemistry 2016; 12 (2) . https://dx.doi.org/10.2174/157340641202160209104115
DOI https://dx.doi.org/10.2174/157340641202160209104115 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Polycystic Ovary Syndrome: A Contemporary Clinical Approach
Current Pharmaceutical Design Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry Prevention of Contrast Induced Nephropathy
Current Drug Therapy Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Vasopressin and Terlipressin in Neonates and Children with Refractory Septic Shock
Current Drug Metabolism Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery